Filing Flows › Praxis Precision Medicines (PRAX) › Takeover & LBO
Is Praxis Precision Medicines (PRAX) a takeover target?
A leveraged buyout does not work for Praxis Precision Medicines on its latest figures: it has no positive EBITDA to borrow against (−$378M over the last 12 months).
Why a leveraged buyout does not fit
A leveraged buyout is paid for mostly with debt that the company's own cash flow repays. Praxis Precision Medicines' EBITDA over the last 12 months was −$378M, so there is nothing to lend against and nothing to repay a loan with: a buyer would have to pay almost entirely with its own money. That is the kind of deal another company — a strategic buyer that wants the products, the pipeline or the technology — makes, not a private-equity fund. The model therefore gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Praxis Precision Medicines would cost about $385.40 a share, $11.2B for all its shares.
| Premium | % | Price a share | All shares |
|---|---|---|---|
| Low end (a quarter of deals paid less) | 22% | $348.29 | $10.1B |
| Median | 35% | $385.40 | $11.2B |
| High end (a quarter paid more) | 45% | $413.95 | $12.1B |
Praxis Precision Medicines' latest quarter
Praxis Precision Medicines, Q4 2024: revenue $7.5M (14× year over year), operating margin -857.0%, net loss $58.7M, operating cash flow −$56.1M. The chart follows the revenue to costs, profit and cash.
Questions
Is Praxis Precision Medicines being acquired?
No headline, 8-K or 13D about a sale is on file in the last year.
Could private equity buy Praxis Precision Medicines?
A leveraged buyout does not work for Praxis Precision Medicines on its latest figures: it has no positive EBITDA to borrow against (−$378M over the last 12 months). With no cash flow to repay a loan, a buyer would pay almost entirely with its own money: a deal for another company (a strategic buyer), not for a private-equity fund.
What would a takeover of Praxis Precision Medicines cost?
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Praxis Precision Medicines would cost about $385.40 a share, $11.2B for all its shares.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.